Literature DB >> 18069767

Effect and mechanism of beta-L-D4A on DNA polymerase alpha.

Yan Li1, Ju-Sheng Lin, Ying-Hui Zhang, Xiao-Yan Wang, Ying Chang, Xing-Xing He.   

Abstract

AIM: To investigate the safety of beta-L-D4A on DNA polymerase alpha.
METHODS: Ion exchange chromatography was used to separate DNA polymerase alpha from crude extract of human Hela cells. Detailed kinetic parameters were determined for beta-L-D4A against DNA polymerase alpha.
RESULTS: DNA polymerase alpha was purified with 4% yield and 31000 units/mg specific activity. The Michaelis constant (Km = 3.22 micromol/L), 50% inhibition concentration (IC50 = 178.49 micromol/L) and inhibition constant (Ki = 126 micromol/L) of beta-L-D4A were determined by kinetic analysis.
CONCLUSION: beta-L-D4A is a more safe nucleoside for hepatitis B virus infection with a lower host toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18069767      PMCID: PMC4171237          DOI: 10.3748/wjg.v13.i46.6243

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  [Effect and mechanism of beta-L-D4A (a novel nucleoside analog) against hepatitis B virus].

Authors:  Jin-ming Wu; Ju-sheng Lin; Na Xie; Feng-chao Jiang; Kuo-huan Liang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-05

2.  [Inhibition of the replication of hepatitis B virus in vitro by a novel nucleoside analogue (beta-L-D4A)].

Authors:  Jin-ming Wu; Ju-sheng Lin; Feng-chao Jiang; Jin-yan Zhang; Kuo-huan Liang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-07

3.  Anti-tumor effects of dehydroaltenusin, a specific inhibitor of mammalian DNA polymerase alpha.

Authors:  Naoki Maeda; Yasuo Kokai; Seiji Ohtani; Hiroeki Sahara; Isoko Kuriyama; Shinji Kamisuki; Shunya Takahashi; Kengo Sakaguchi; Fumio Sugawara; Hiromi Yoshida; Noriyuki Sato; Yoshiyuki Mizushina
Journal:  Biochem Biophys Res Commun       Date:  2006-11-14       Impact factor: 3.575

4.  Human DNA polymerase alpha uses a combination of positive and negative selectivity to polymerize purine dNTPs with high fidelity.

Authors:  Jeff Beckman; Kristi Kincaid; Michal Hocek; Thomas Spratt; Joachim Engels; Richard Cosstick; Robert D Kuchta
Journal:  Biochemistry       Date:  2007-01-16       Impact factor: 3.162

5.  Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B.

Authors:  Shiv Kumar Sarin; Ajit Sood; Manoj Kumar; Anil Arora; Deepak Amrapurkar; Barjesh Chander Sharma; Ashokananda Konar; Yogesh Kumar Chawla; Rajendra Kumar Jain; Vijay Nanda; Arun Kumar; Syed Hissar; Piramal Lavate; Deepak Lahoti
Journal:  Am J Gastroenterol       Date:  2007-01       Impact factor: 10.864

6.  Epicatechin conjugated with fatty acid is a potent inhibitor of DNA polymerase and angiogenesis.

Authors:  Kiminori Matsubara; Akiko Saito; Akira Tanaka; Noriyuki Nakajima; Reiko Akagi; Masaharu Mori; Yoshiyuki Mizushina
Journal:  Life Sci       Date:  2007-02-02       Impact factor: 5.037

7.  Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection.

Authors:  Lucio Caccamo; Francesca Agnelli; Paolo Reggiani; Umberto Maggi; M Francesca Donato; Stefano Gatti; Giovanni Paone; Ernesto Melada; Giorgio Rossi
Journal:  Transplantation       Date:  2007-05-27       Impact factor: 4.939

8.  Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.

Authors:  Urvi M Parikh; Shannon Zelina; Nicolas Sluis-Cremer; John W Mellors
Journal:  AIDS       Date:  2007-07-11       Impact factor: 4.177

9.  Appropriate use of interferon for treatment of chronic hepatitis B.

Authors:  Jia-Horng Kao
Journal:  Hepatol Res       Date:  2007-07       Impact factor: 4.288

10.  Effect of novel benzoylphenylurea derivatives on DNA polymerase alpha activity using the synthesome-based in vitro model system.

Authors:  Waleed Abdel-Aziz; Robert Hickey; Martin Edelman; Linda Malkas
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.